Skip to navigation | Skip to main content | Skip to footer
Menu
Menu Search the University of Manchester siteSearch
Search type

Alternatively, use our A–Z index

Professor Andrew Hughes (MA PhD MRCP FFPM PGCert) - publications

List of publications

2014

2013

2012

  • Greystoke, A., Dean, E., Saunders, M. P., Cummings, J., Hughes, A., Ranson, M., ... Renehan, A. G. (2012). Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer.British Journal of Cancer, 107(9), 1518-1524. DOI: 10.1038/bjc.2012.416. Publication link: d5a144e7-d0e4-445e-a696-9ec484e13805 | PubMed:22996610
  • Delouvrié, B., Al-Kadhimi, K., Arnould, J-C., Barry, S. T., Cross, D. A. E., Didelot, M., ... Warin, N. (2012). Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2.Bioorganic & medicinal chemistry letters, 22(12). DOI: 10.1016/j.bmcl.2012.04.061. Publication link: b3f55dab-79f6-4b67-91f6-794710267ffd | PubMed:22572578
  • Krebs, M. G., Hou, J-M., Sloane, R., Lancashire, L., Priest, L., Nonaka, D., ... Dive, C. (2012). Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 7(2), 306-315. DOI: 10.1097/JTO.0b013e31823c5c16. Publication link: af24c102-e1d8-4377-9876-e5c64c46f896 | PubMed:22173704
  • Delouvrié, B., Al-Kadhimi, K., Arnould, J-C., Barry, S. T., Cross, D. A. E., Didelot, M., ... Warin, N. (2012). Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1.Bioorganic & medicinal chemistry letters, 22(12). DOI: 10.1016/j.bmcl.2012.04.063. Publication link: 73fa7417-9d64-4425-ac50-2b8211c54717 | PubMed:22575869
  • Khoja, L., Backen, A., Sloane, R., Menasce, L., Ryder, D., Krebs, M., ... Dive, C. (2012). A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. British Journal of Cancer, 106(3), 508-516. DOI: 10.1038/bjc.2011.545. Publication link: 833355de-8e00-4bb2-b516-5b318d86d49b | PubMed:22187035

2011

  • Krebs, M. G., Sloane, R., Priest, L., Lancashire, L., Hou, J. M., Greystoke, A., ... Blackhall, F. H. (2011). Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. Journal of Clinical Oncology, 29(12), 1556-1563. DOI: 10.1200/JCO.2010.28.7045. Publication link: c5010707-0ef5-489d-86c9-9e46be19c05e | PubMed:21422424

2008

2006

2004

2003

  • Hughes, A. (2003). To ensure regulatory success, when and what type of pharmacokinetics studies should I do in special patient groups. In Global Drug Development. UK: Brookwood Medical Publications. . Publication link: 6af3cee8-849c-4859-b7be-a6d5bb399a4a

2002

1998